Investigation into the discontinuation status of Gefapixant Citrate in Japan

Gefapixant Citrate (Gefapixant Citrate) was once marketed in Japan as an original drug for the treatment of patients with chronic cough. The drug specification is usually 45mg*100 tablets, which is a prescription oral preparation, mainly for adults with refractory chronic cough. During its launch in Japan, the drug was considered an important innovative drug in the field of chronic cough treatment because its mechanism of action targeting the P2X3 receptor is different from traditional antitussives, providing a new treatment option for patients with long-term chronic cough.

However, recent information shows that the Japanese version Gefapixant has been discontinued or discontinued in the Japanese market. This phenomenon may be related to market strategy, patent management, pharmaceutical supply chain or sales channel adjustments. It is worth noting that the suspension of production does not mean that there is a problem with the efficacy or safety of the drug, but is more a decision made by the company based on global market layout and commercial considerations. For Japanese patients taking Gefapixant, doctors often provide alternative treatment options based on clinical assessment or assist in obtaining the drug through specific channels to ensure continuity of treatment.

Elsewhere overseas,Gefapixant remains on the market, with multiple international clinical studies supporting its efficacy. For Japanese patients, the shutdown means access to originator drugs may be limited, but drugs are still available through some clinical trials or licensing channels. In addition, the suspension of production in the Japanese market also reflects the dynamic changes in the field of chronic cough drug research and development, that is, the launch cycle of innovative drugs may be affected by multiple factors, including production costs, market demand and regulatory requirements.

Taken together, the Japanese market The discontinuation status of Gefapixant reminds clinicians and patients to pay attention to drug supply and alternative treatment options, while maintaining an understanding of the latest advances in targeted therapies for chronic cough, so as to adjust treatment plans in a timely manner to ensure that patient symptoms are effectively managed.

Reference materials:https://synapse.patsnap.com